Clinical trial NCT04714996: Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy
Official title: A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Drug Resistant Epilepsy
Lead sponsor: ES Therapeutics Australia Pty Ltd
Sponsor class: INDUSTRY
First posted: 2021-01-20
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This is a Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study with cross-over to Evaluate the Efficacy, Safety, and Pharmacokinetics of ES-481 in Adult Patients with Drug Resistant Epilepsy


Eligibility criteria: Inclusion Criteria:

1. The subject/legal guardian must be able to understand and sign the Human Research Ethics Committee-approved written Informed Consent Form (ICF) and privacy language as per national regulations (e.g., HREC and TGA requirement in Australia) prior to any study-related procedures being performed
2. The subject is a male or female 18 to 70 years of age, inclusive
3. The subject must have a history of drug resistant epilepsy (as per the ILAE definition)
4. The subject must be taking 1 to 4 antiepileptic drugs (AED) and must be on a stable dose of the AEDs for at least four (4) weeks prior to entering the 28-day screening period
5. If VNS implanted, the stimulation setting must have been stable for at least four weeks prior to entering the 28-day screening period
6. The subject/legal guardian must be able to use the seizure dairy to record seizure throughout the study
7. The subject must experience at least four (4) countable seizures within a 28-day period.

   For continued enrollment into Treatment Period 1, each subject will be confirmed to have experienced at least four (4) countable seizures in the 28-day screening period
8. The subject must have interictal epileptiform discharges and/or seizure with an average frequency of at least one (1) per hour on EEG recording.

   For continued enrollment into Treatment Period 1, this will be confirmed by a 24-hour EEG performed during the 28-day screening period.
9. The subject is willing and able to comply with the study requirements

Exclusion Criteria:

1. Unwilling or inability to follow the procedures specified by the protocol
2. Pregnancy or breast feeding
3. Women of child-bearing potential and men who are unable or unwilling to take adequate contraceptive precautions, including one of the following:

   Hormonal contraception (birth control pills, injected hormones or vaginal ring) Intrauterine device Barrier methods (condom or diaphragm) combined with spermicideSurgical sterilization (hysterectomy, tubal ligation, or vasectomy)
4. Current treatment for another significant medical disorder, such as diabetes, or heart disease or an untreated disorder, that is discovered during the 28-day screening period and might interfere with the study in the opinion of the Principal Investigator
5. An abnormality on clinical laboratory tests, physical examination, EEG or ECG that might increase the risks associated with trial participation or investigational product administration, such as hepatic enzyme elevation greater than twice normal and/or a GFR \< 60 mL/min/1.73 m2
6. History (within the month) of illicit drug use or alcohol dependence, and a commitment by the subject to not take the illicit drugs during the study
7. Concomitant treatment with more than four (4) AEDs
8. Evidence for a potentially progressive neurologic disorder, such as a brain tumor, multiple sclerosis or dementia
9. Planned epilepsy surgery within six months of enrollment

Primary outcomes:
measure: Seizure Frequency
timeFrame: Continuous and at Days 1, 8, 15, 22, 28, 43, 50, 57, 64 and 70
Secondary outcomes:
measure: Hamilton Anxiety Rating Scale (HAM-A)
timeFrame: Collected at screening, Days 1, 8, 15, 22, 28, 43, 50, 57, 64 and 70
measure: Hamilton Depression Rating Scale (HDRS)
timeFrame: Collected at screening, Days 1, 8, 15, 22, 28, 43, 50, 57, 64 and 70
measure: Adverse Events
timeFrame: Collected at screening, Days 1, 8, 15 22, 28, 43, 50, 57, 64 and 70
measure: Laboratory Assessments - Hematology
timeFrame: Collected at screening, Days 1, 8, 15 22, 28, 43, 50, 57, 64 and 70
measure: Laboratory Assessments - Chemistry
timeFrame: Collected at screening, Days 1, 8, 15 22, 28, 43, 50, 57, 64 and 70
measure: Pharmacokinetics (PK) - Cmax
timeFrame: Collected at screening, Days 1, 8, 15 22, 28, 43, 50, 57, 64 and 70
measure: Pharmacokinetics (PK) - Tmax
timeFrame: Collected at screening, Days 1, 8, 15 22, 28, 43, 50, 57, 64 and 70
measure: Pharmacokinetics (PK) - AUC0-t
timeFrame: Collected at screening, Days 1, 8, 15 22, 28, 43, 50, 57, 64 and 70
measure: Pharmacokinetics (PK) - AUC0-inf. T1/2
timeFrame: Collected at screening, Days 1, 8, 15 22, 28, 43, 50, 57, 64 and 70
measure: Pharmacokinetics (PK) - CL/F
timeFrame: Collected at screening, Days 1, 8, 15 22, 28, 43, 50, 57, 64 and 70
measure: Pharmacokinetics (PK) - Vz/F
timeFrame: Collected at screening, Days 1, 8, 15 22, 28, 43, 50, 57, 64 and 70
Other outcomes:
Locations:
city: Herston
country: Australia
facility: Royal Brisbane and Women's Hospital
state: Queensland
city: Heidelberg
country: Australia
facility: Austin Hospital
state: Victoria
city: Melbourne
country: Australia
facility: Alfred Health
state: Victoria
city: Parkville
country: Australia
facility: Royal Melbourne Hospital
state: Victoria
Study officials:
affiliation: The Alfred
name: Terence O'Brien
role: PRINCIPAL_INVESTIGATOR
References: